Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Neurofibromatosis 1 · Plexiform Neurofibroma (PN)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 145 (final count)
- Started
- Nov 19, 2021
- Main results expected
- Aug 5, 2024
- Fully finished
- Feb 15, 2029
- Results posted
- Oct 20, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Partial and Complete Response Rate (ORR) by End of Cycle 16 Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) in Participants With NF1 Who Have Symptomatic, Inoperable PN.
Measured over: From first dose up until progression (if it occurs prior to the end of Cycle 16), or the last evaluable assessment up to and including the end of Cycle 16, excluding MRI during prolonged study intervention interruption (defined as interruption >= 28 days)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04924608 · record last updated 2026-03-23 · checked 2026-11-09 15:47 UTC